Highlights d MMP-2 and MMP-9 activity occurs at the blood-brain barrier d Cytokines derived from infiltrating leukocytes control MMP activity at the BBB 
INTRODUCTION
Chemokines are central for migration of several cell types; however, their levels and efficacy of action depend on additional factors, such as cytokines and/or their selective proteolytic processing. Particularly in models of autoimmunity, T cell-derived cytokines define the characteristics of different T cell subpopulations and play decisive roles in shaping the microenvironment within the target organ, which collectively regulate immune cell infiltration. Experimental autoimmune encephalomyelitis (EAE) is a widely used T cell-mediated model for the early inflammatory stages of multiple sclerosis (MS) that depends on a special microenvironment at the blood-brain barrier (BBB). Due to a unique double-basement membrane structure of cerebral blood vessels (Sixt et al., 2001) , EAE has proven to be a valuable model for investigating the steps in leukocyte migration into the CNS. Initial penetration of the BBB requires transmigration of the endothelial monolayer and its underlying endothelial basement membrane, followed by accumulation in the perivascular space where leukocytes are retained for several days. Within the perivascular cuff, leukocytes are reactivated and the balance of effector versus regulatory T cell populations is determined (Kö rner et al., 1997) , which permits subsequent transmigration of the parenchymal basement membrane and glia limitans and infiltration of the CNS parenchyma. Only then do disease symptoms become apparent, indicating that migration out of the perivascular cuff is a disease-limiting step (Agrawal et al., 2006) . Effector T cell populations critical for the pathogenesis of EAE include T helper type 1 (T H 1) and interleukin-17 (IL-17)-producing T helper (T H 17) cells, which differ in their cytokine profiles and, thereby, proinflammatory properties. T H 1 cells are characterized by secretion of tumor necrosis factor (TNF-a) and interferon-g (IFN-g), whereas TNF-a and IL-17 are representative of the T H 17 cell lineage (Weaver et al., 2007) , which is considered to be a pro-encephalitogenic population. However, precisely how these cytokines influence the different steps in immune cell penetration of tissues remains inconclusive.
Data suggest that penetration of the endothelial and parenchymal barriers are independent steps involving distinct molecular mechanisms. While several factors have been identified that play important roles in penetration of the endothelial cell monolayer (Engelhardt, 2006) and its basement membrane (Sixt et al., 2001; Wu et al., 2009) , comparatively little is known about the subsequent penetration of the parenchymal border. Chemokines such as CXCL12 have been shown to be required for holding T cells in the perivascular cuff, and its proteolytic degradation by MMPs releases leukocytes to migrate into the CNS parenchyma (McCandless et al., 2006) . TNF-a also has been implicated in this step as TNF-a knockout (Tnf -/-) mice show massively enlarged perivascular cuffs and delayed onset of disease symptoms (Kö rner et al., 1997) . Although the precise mechanism of TNF-a action is not clear, differences in chemokine profiles in the CNS of Tnf -/-mice compared to wild-type (WT)
littermates have been proposed to delay the initial leukocyte penetration of the parenchymal barrier (Murphy et al., 2002) . In addition, in situ zymography has revealed matrix metalloproteinase (MMP)-2 and MMP-9 activity at sites of leukocyte penetration of the parenchymal border (Agrawal et al., 2006) . Young MMP-9 knockout mice are partially resistant to EAE (Dubois et al., 1999) , while MMP-2 and MMP-9 double-knockout (DKO) mice are completely resistant to disease development (Agrawal et al., 2006) , suggesting a central role for these MMPs in disease induction.
In addition to CXCL12, several chemokines play a role in leukocyte recruitment in EAE (Ransohoff, 2009) , some of which are constitutively expressed in the CNS parenchyma and upregulated during EAE and others that are newly synthesized (Ambrosini et al., 2005; Glabinski et al., 1995; Murphy et al., 2002) . However, CNS-specific chemokine expression never precedes histopathological signs of EAE (Glabinski et al., 1995; Huang et al., 2000) , indicating that initial leukocyte infiltration into the CNS is a prerequisite for the expression of chemokines. Proinflammatory cytokines secreted from infiltrating cells, including TNF-a, IFN-g, and IL-17, can directly influence chemokine levels by inducing mRNA expression (Murphy et al., 2002) and stability (Hartupee et al., 2007) , but they also can have indirect effects by modulating protease levels and activities, including those of MMPs, which in turn can alter chemokine activation or inactivation and their expression (Corry et al., 2002; McQuibban et al., 2000; Van den Steen et al., 2000) .
Using bone marrow (BM) chimeric mice lacking immune-cell or tissue-resident sources of MMP-2 and MMP-9 or TNF-a in EAE experiments combined with in vitro studies, we show here that inflammatory cytokines, chemokines, and activated MMP-2 and MMP-9 act in concert at the parenchymal border to determine whether or not leukocyte infiltration into the CNS parenchyma occurs.
RESULTS
Mice Lacking MMP-2 and MMP-9 in Immune and Tissue-Resident Cells Have Enlarged Perivascular Cuffs To distinguish between infiltrating leukocyte and CNS-resident sources of the gelatinases, WT, Mmp2 À/À or Mmp9 À/À , and DKO recipients carrying WT BM, and therefore WT leukocytes, were actively induced for EAE. Conversely, DKO BM was transferred to WT recipients to generate mice lacking a leukocyte source of MMP-2/9, and EAE was actively induced. In the absence of a tissue-resident or leukocyte source of MMP-2 and MMP-9, the appearance of EAE symptoms was delayed and disease symptoms were less severe than in WT or single-KO chimeric mice ( Figure 1A ), indicating that MMP-2/9 from both leukocytes and resident cells contribute to EAE induction and severity. No differences were measured in numbers of CD45 + leukocytes, CD4 + or CD8 + T cells, and CD11b + macrophages in the CNS during EAE in any of the chimeric mice carrying WT BM. Only WT mice carrying DKO BM showed lower numbers of all immune cells ( Figures 1B, 1C , S1A, and S1B), suggesting an impaired immune response in the absence of leukocyte-derived MMP-2 and MMP-9. Since these chimeric mice develop EAE symptoms, T cell priming in the periphery may be less efficient than when MMPs are expressed by immune cells but activated effector T cells can be generated. This was confirmed by in vitro experiments that revealed a reduced antigen-specific response of DKO CD4 + T cells ( Figure S1C ), but an absence of defects in anti-CD3-induced T cell proliferation ( Figure S1D ). Immunofluorescence staining of brain and spinal cord sections, using antibodies to pan-laminin and CD45 to visualize the endothelial and parenchymal basement membranes and infiltrating leukocytes, suggested enlarged perivascular cuffs in mice lacking an immune-cell or tissue-resident source of MMP-2 and MMP-9 ( Figure 1D ). Stereological analyses, involving MRI determination of tissue volumes ( Figure S1E ) and subsequent calculation of cuff numbers and cuff area/brain or spinal cord using serial sections throughout the entire tissue stained for pan-laminin and CD45, revealed that mice lacking a leukocyte or tissue-resident source of MMP-2 and MMP-9 had fewer but larger cuffs at EAE onset ( Figures 1E and 1F ). At peak EAE, when significant numbers of leukocytes had penetrated the parenchymal border, there were fewer cuffs but they remained enlarged in DKO mice carrying WT BM (Figures S1F and S1G), suggesting a more prominent role of CNS-derived MMPs for penetration of the parenchymal border.
Enlarged cuffs without differences in total immune cell infiltration suggests either enhanced leukocyte migration into or reduced migration out of the cuff. Transfer of CD45. (Wu et al., 2009) , revealed equal numbers of donor T cells in all recipients (Figures S2A and S2B) . This suggests that the enlarged cuffs in mice lacking a resident source of MMP-2 and MMP-9 was due to reduced migration out of the cuff. In both brains and spinal cords of mice lacking a leukocyte or tissue-resident source of MMP-2 and MMP-9, fewer cuffs showed leukocyte penetration at EAE onset compared to peak ( Figure S3A ). Immunohistochemistry for myelin basic protein revealed no demyelination ( Figure S3B ) nor detectable MMP-2/9 activity by in situ zymography surrounding cuffs until leukocyte penetration had occurred and EAE symptoms were apparent (Figures 1D and S3C; Agrawal et al., 2006) .
Mice Lacking T Cell-Derived TNF-a Also Have Enlarged Cuffs Enlarged perivascular cuffs also have been reported in Tnf À/À mice induced for EAE (Kö rner et al., 1997) . As T cell-derived TNF-a has been shown to be responsible for this phenotype (Murphy et al., 2002) , we adoptively transferred encephalitogenic Tnf À/À T cells to WT recipients and examined cuff sizes in correlation with MMP-2/9 activity. EAE was delayed and reduced in severity in mice lacking T cell-derived TNF-a (Figure 2A) , as observed in Tnf À/À mice induced for EAE ( Figure S4A ; Kö rner et al., 1997) . Immunofluoresence staining and stereological analyses revealed similarly enlarged cuffs in TNF-a-deficient mice ( Figures 2B-2D and S4B-S4F), as observed in the MMP-2/9 BM chimeric mice, with equivalent numbers of immune cells at onset and peak EAE ( Figures S4G and S4H ), which correlated with no detectable MMP-2 and MMP-9 activity using gel zymography and in situ zymography ( Figure 2B ). At peak EAE, when considerable numbers of leukocytes had penetrated the parenchymal border, MMP-2/9 activity was detectable and cuff sizes were reduced ( Figures 2B-2D and S4B-S4F). Figure 2E ), draining lymph nodes (LNs) and spleens ( Figure S4I ) compared to WT mice. Elevated levels of IFN-g was corroborated by ELISA of CNS extracts of WT and Tnf -/-mice ( Figure 2F ). Accordingly, conditioned media from cultured MOG 35-55 -specific Tnf -/-and WT CD4 + T cells contained identical levels of IL-4, IL-10, IL-6, IL-17, and IL-1a, but elevated IFN-g in Tnf -/-samples ( Figure S4J ). Hence, Tnf -/-CD4 + T cells not only lack TNF-a, but also have elevated IFN-g levels throughout the disease course ( Figure S4K ). Previous studies have identified MMP-9 secretion by T cells (Dubois et al., 1999) and MMP-2 and MMP-9 by macrophages (Agrawal et al., 2006) . In situ hybridization of WT mice carrying DKO BM, and hence no immune-cell source of MMP, showed that astrocytes at the BBB also can express MMP-9, but only after EAE induction ( Figure 3A ). This was confirmed using qPCR, gel zymography, and ELISA of cultured astrocytes, revealing constitutive expression of pro-and activated MMP-2 and upregulation of pro-and activated MMP-9 by TNF-a and, to a lesser extent, by IL-17 and inhibition by IFN-g ( Figures 3B-3D) . A similar trend but with milder effects was observed for MMP-2 ( Figures  3B-3D ). These results are consistent with the reported effects of cytokines on MMP-2 and MMP-9 expression in other tissues (Rosenberg, 2002) . Taken together, the data suggest that MMP-9 secretion by astrocytes at the BBB is enhanced by T cell-derived TNF-a/IL-17 and inhibited by IFN-g.
MMPs Are Required for Leukocyte Chemotaxis out of the Cuff
As chemokines are required for attracting T lymphocytes into the CNS parenchyma during EAE, we tested the chemotactic potential of CNS extracts collected at peak EAE from MMP BM chimeric mice and from Tnf -/-adoptive transfer experiments. CNS extracts were added to the bottom chamber of a transwell system and primary CD4 + encephalitogenic T cells were placed in the top chamber. Transmigrated cells were counted at 6 hr. CNS extracts from WT or Mmp2 -/-and Mmp9 -/-chimeric mice had approximately the same chemotactic potential, which was signficantly reduced in CNS extracts from mice lacking a tissue-resident source of MMP-2 and MMP-9 ( Figure 4A ) or lacking a T cell source of TNF-a ( Figure 4B ). To identify the missing chemotactic factor/s, the major chemokines implicated in EAE (CCL2, CCL3, CCL5, CCL20, CXCL10, and CXCL12) (Glabinski et al., 2005; Huang et al., 2000) were measured in CNS extracts at early and peak EAE. Significantly lower levels of all chemokines were measured in mice lacking tissue-resident sources of MMP-2 and MMP-9 or T cell-derived TNF-a, with the (legend continued on next page) exception of CXCL12, which was elevated at peak EAE in all situations ( Figures 4C, 4D , S5A, and S5B). As MMP-2 and MMP-9 inactivate CXCL12 (Vergote et al., 2006) , we also measured cleaved inactivated CXCL12, revealing significantly reduced levels in mice lacking MMP-2 and MMP-9 or T cell-derived TNF-a, suggesting higher levels of full-length CXCL12 ( Figures  4C and 4D ).
Astrocyte-Derived MMP-2 and MMP-9 Enhance T Cell Chemotaxis As astrocytes express chemokines (Ambrosini et al., 2005; Glabinski et al., 1995; Kim et al., 2014) and, as shown here, MMP-2 and MMP-9, and they are strategically located at the parenchymal border, we utilized cultured astrocytes from WT and DKO mice to examine whether a relationship exists between MMPs and chemotactic potential. Conditioned media from WT-, Mmp2
-/--, Mmp9 -/--, or DKO-cultured astrocytes were used as chemoattractants in the lower chamber of a transwell system, and primary encephalitogenic T cells were placed in the upper chamber. Transmigrated cells were measured by flow cytometry after 6 hr. WT, Mmp2
, and Mmp9 -/-astrocyte-conditioned media showed a basal chemotactic potential not present in DKO-conditioned medium ( Figure 5A ), which was enhanced by the addition of activated MMP-2, MMP-9, or MMP-3, but not other MMPs ( Figure 5B ). MMP-3 activates MMP-2 and MMP-9 (Ogata et al., 1992) and thereby probably increased the activated fraction of endogenous MMP-2 and MMP-9 present in the astrocyte-conditioned medium. Conversely, the basal chemotactic activity of WT astrocyte-conditioned medium was inhibited by MOBSAM, a chemical inhibitor that shows concentration-dependent inhibition of specific MMPs (Matsumura et al., 2005) . Low doses of MOBSAM (10 nM) inhibit MMP-2 activation only, whereas 50 nM MOBSAM inhibits both MMP-2 and MMP-9 and >100 nM inhibits MMP-8, MMP-12, and MMP-13 (Matsumura et al., 2005) . As no suppression of astrocyte chemotactic activity was observed at 10 nM MOBSAM, whereas 50 nM and 150 nM showed the same degree of inhibition ( Figure 5C ), this indicates that MMP-2 and MMP-9 are sufficient for regulation of the astrocyte-derived chemotactic activity. The data suggest that astrocytes could be a source of chemotactic factors for encephalitogenic T cells, the activity of which is enhanced by MMP-2 or MMP-9. ELISA was used to investigate whether this chemotactic potential correlated with chemokine levels in the conditioned media. WT astrocyte-conditioned medium contained CCL2, CCL3, CCL5, CCL20, and CXCL10 ( Figure 5D ). CXCL12 was not detectable and is considered to be secreted by perivascular cells (McCandless et al., 2006) . Treatment of WT astrocytes with activated MMP-2 or MMP-9 increased the levels of all detectable chemokines, while inhibition of MMP activation with 50 nM MOBSAM had a suppressive effect ( Figure 5D ), consistent with the transmigration data and suggesting endogenous MMP expression by astrocytes.
Pro-and Anti-Inflammatory Cytokines Modulate T Cell Chemotaxis in a MMP-Dependent Manner Since TNF-a and IFN-g affect MMP levels, we investigated the chemotactic potential of astrocyte-conditioned media in the presence and absence of TNF-a or IFN-g, and correlated this with measurable chemokine levels. To mimic the in vivo situation, astrocytes were coincubated with primary T H 1 or T H 17 cells, and the chemotactic potential of the conditioned media was tested. CFSE-labeled CD4 + T cells were added to the upper chamber of a transwell system to distinguish them from T cells coincubated with astrocytes, and transmigrated CFSE + cells were quantified by flow cytometry after 12 hr. The chemotactic activity of the astrocytes was significantly enhanced by coincubation with WT T H 17 cells, which secrete TNF-a and IL-17, while coculture with T H 1 cells, which secrete TNF-a and IFN-g, had little effect. T H 17 or T H 1 cells alone had no effect ( Figure 5E ). Enhanced chemotaxis also was measured when WT astrocytes were stimulated with TNF-a or IL-17, with TNF-a plus IL-17 having mild additive effects ( Figure 5F ). By contrast, conditioned medium from IFN-g-treated astrocytes inhibited both the basal chemotactic activity of astrocyte-conditioned medium and suppressed the enhanced chemotactic effects of TNF-a and IL-17 ( Figure 5F ). In the absence of astrocytes, cytokines alone had no effect on T cell transmigration ( Figure 5F ). When the same experiments were performed with DKO astrocyte-conditioned media, the basal chemotactic potential and the enhancing effects of TNF-a and IL-17 were suppressed ( Figure 5G ), and were rescued by the addition of activated MMP-2 or MMP-9 ( Figure 5A ). Corresponding measurement of EAE-relevant chemokines in the cytokine-treated astrocyte-conditioned media revealed the absence of a strict correlation between chemokine levels and measured chemotaxis. While TNF-a and IL-17 both enhanced transmigration, TNF-a but not IL-17 increased chemokine levels, and IFN-g, which suppressed transmigration, did not consistently reduce chemokine levels (Figures 5H and S6) . These data support a role for TNF-a alone or in combination with IL-17 in inducing chemokine secretion by astrocytes, but also reinforces the pivotal role of MMP-2 and MMP-9 on the efficacy of astrocyte-derived chemotactic factors. Consistent with transmigration data, DKO astrocyteconditioned medium contained significantly lower levels of all chemokines and a reduced response to TNF-a, IL-17, and IFN-g ( Figure 5H ). Together with the strong upregulation of chemokine levels in response to MMP-2/9 treatment of astrocytes, in particular CXCL10 ( Figure 5D ), this suggests that MMP-2 and MMP-9 may promote chemokine release by astrocytes.
(E and F) (E) Chemotactic activity of WT astrocytes is enhanced by coincubation with T H 17 but not T H 1 cells and by (F) TNF-a or IL-17, while IFN-g has suppressive effects. TNF-a plus IL-17 have additive effects and IFN-g inhibits the enhanced chemotactic effects of TNF-a and IL-17. (G) DKO astrocyte-conditioned medium has reduced chemotactic potential, which is not affected by proinflammatory chemokines. (H) Chemokine levels measured by ELISA in conditioned media from WT or DKO astrocytes treated with proinflammatory cytokines. Experiments were performed three times using different astrocyte preparations, with triplicates/treatment in each experiment. Data are means ± SEM. *p < 0.05,**p < 0.01,***p < 0.001. See also Figure S6 .
MMP-2 and MMP-9 Induce Chemokine Expression
We therefore investigated whether MMP-2 and MMP-9 of astrocytes impact on the major pathway associated with chemokine expression, namely PI3K/p-AKT/necrosis factor kB (NF-kB) (Quinones et al., 2008; Thompson and Van Eldik, 2009; van Loo et al., 2006) . Western blots revealed that MMP-2-or MMP-9-treated astrocytes had increased levels of phosphorylated AKT and p-P65 ( Figure 6A ), suggesting increased NF-kB translocation to the nucleus. Similar effects were observed with TNF-a ( Figure 6A ), which is known to induce chemokine expression via NF-kB signaling (Quinones et al., 2008; Thompson and Van Eldik, 2009 ). astrocytes show reduced chemotactic potential compared to WT astrocytes, (E) significantly reduced chemokine levels, and absence of MMP-2-or MMP-9-induced upregulation of chemokines. Data are means ± SEM of three to four experiments with three to six replicates. *p < 0.05,**p < 0.01, ***p < 0.001. See also Figure S7 .
To determine how MMPs could enhance NF-kB signaling, we turned to two known cell-surface MMP substrates on astrocytes: (1) dystroglycan, which anchors astrocyte endfeet to the parenchymal basement membrane (Agrawal et al., 2006) ; and (2) Notch-1, which is important for astrocyte development (Cau and Blader, 2009) . Dystroglycan can signal via PI3K/p-AKT in skeletal muscle, but only when anchored to one of its ligands, laminin (Langenbach and Rando, 2002) . As MMP-2 and MMP-9 cleave dystroglycan on astrocytes, disconnecting it from its ligands in the parenchymal basement membrane (Agrawal et al., 2006) , it is unlikely to be associated with increased NF-kB signaling. By contrast, cleavage of Notch-1 by MMP-9 can lead to the inhibition of PTEN, thereby upregulating PI3K/p-AKT and NF-kB signaling (Garg et al., 2010) . Western blots revealed inhibition of PTEN by MMP-2 or MMP-9 treatment of WT astrocytes ( Figure 6A) , and a corresponding upregulation of Notch-1-specific transcription factors, Hes1 and Hes5 ( Figure 6B ). DKO astrocytes showed reduced Hes1 and Hes5 expression, which was rescued by the addition of MMP-2 or MMP-9 ( Figure 6B ). Notch-1 À/À astrocytes ( Figure 6C) showed reduced basal chemotactic activity that was not rescued by MMP-2 or MMP-9 ( Figure 6D ), and showed no upregulation of chemokines in response to MMP-2 or MMP-9 treatment ( Figure 6E ). Control experiments with dystroglycan KO (Dag À/À ) astrocytes ( Figure S7A ) showed no difference compared to WT astrocytes in basal chemotactic potential, T cell transmigration in response to MMP-2 or MMP-9 ( Figure S7B ), or upregulation of chemokines ( Figure S7C ). Hence, MMP-2 and MMP-9 may stimulate Notch-1 signaling in astrocytes, leading to the inhibition of PTEN and subsequent induction of p-AKT/ NF-kB-signaling pathways and enhanced chemokine secretion.
MMP-2 and MMP-9 Also Modulate Chemokine Availability at the Parenchymal Border MMP-2 and MMP-9 also can modulate chemokine activity or availability by selective cleavage (Van den Steen et al., 2000 Steen et al., , 2003 . While this is likely to occur in EAE, it is technically impossible to prove as it requires quantities of chemokines and their fragments for detection that cannot be extracted from the low numbers of small perivascular cuffs. We therefore analyzed the in vivo localization of key EAE chemokines in perivascular cuffs and at the parenchymal border using the antibodies available (CXCL12, CCL3, and CXCL10) in immunofluorescence confocal microscopy. CCL2, a further critical EAE chemokine that is inactivated by MMPs (McQuibban et al., 2002) , was not investigated, as it has been extensively studied by others showing broad distribution in the cuff and CNS parenchyma (Paul et al., 2014 , 2006) . Triple staining for pan-laminin, CD45, and CXCL12 antibodies localized CXCL12 within cuffs and in the surrounding CNS parenchymal at onset and peak EAE ( Figure 7A) . Staining for cleaved CXCL12 demonstrated its localization in the CNS parenchyma only ( Figure 7B ), indicating that cleavage not only inactivates CXCL12, but also releases it from local retention, as reported by others (De La Luz Sierra et al., 2004) . In mice lacking an immune-cell or tissue-resident source of MMPs, staining with the antibody to full-length + cleaved CXCL12 was restricted to the perivascular cuffs, with little or no signal for cleaved CXCL12 ( Figure 7B ). Staining for CCL3 was restricted to the perivascular cuffs (Figure 7C) , while CXCL10 occurred mainly in the CNS parenchymal surrounding cuffs and was detected only upon leukocyte penetration of the parenchymal border ( Figure 7D ). Double staining with GFAP revealed its localization close to astrocytes (Figure 7D) , as previously reported (Carter et al., 2007) . Staining for CCL3 and CXCL10 were not altered in mice lacking MMPs (not shown).
CXCL12 and CCL3 are inactivated by MMP-2 and MMP-9 (McQuibban et al., 2001; Vergote et al., 2006) . CXCL10 is cleaved by MMP-9 (Van den Steen et al., 2003) . However, the effect of cleavage on its chemotactic activity has not been reported. We therefore tested whether the chemotactic effect of CXCL10 for encephalitogenic T cells is altered by MMP-2/9 treatment using a transwell system. To mimic the in vivo situation, CXCL12 and CXCL10 were added alone or together, in the presence or absence of MMP-2 or MMP-9. Comparisons were made with CCL21, as an example of a chemokine that is not cleaved by MMPs. MMP-2 or MMP-9 treatment of CXCL12 significantly reduced its chemotactic potential but had no effect on CXCL10, while CXCL12 plus CXCL10 had additive effects that were reduced to levels measured with CXCL10 alone in the presence of MMP-2 or MMP-9 ( Figure 7E) .
Hence, MMP-2/9 derived from infiltrating cells or CNS-resident cells can inactivate CXCL12 and CCL3, releasing inactivated CXCL12 into the CNS parenchyma and permitting infiltrating T cells to respond to other chemokines in the CNS parenchyma, such as CXCL10, which are not affected by the MMPs.
DISCUSSION
Leukocyte penetration of the parenchymal border is a ratelimiting step in the induction of EAE symptoms (Agrawal et al., 2006; Toft-Hansen et al., 2006) . We showed here that both immune-cell and tissue-resident sources of MMP-2 and MMP-9 are required for this step and act specifically at the parenchymal border to promote leukocyte migration out of the perivascular cuff. We showed that the balance of leukocyte-derived inflammatory cytokines, TNF-a versus IFN-g, regulate mainly MMP-9 secretion and activation by astrocytes at the parenchymal border, which can impact on levels and/or activity of chemokines that attract the encephalitogenic T cells into the CNS to induce EAE symptoms. TNF-a and IL-17 promote MMP-9, and to a lesser extent MMP-2, secretion and activation, while IFN-g acts as a negative regulator of their secretion and activation, as reported in other systems (Di Girolamo et al., 2006; Ho et al., 2008) .
In the absence of a CNS-resident source of MMP-2 and MMP-9, immune cell migration to the CNS and into the perivascular cuff was not altered. However, cuffs were larger and penetration of the parenchymal border and onset of disease symptoms were significantly delayed, which correlated with significantly lower levels of most of the EAE-relevant chemokines in the CNS, with the notable exception of CXCL12, and reduced clinical symptoms. This is consistent with previous reports that CNSspecific chemokine mRNA expression never precedes histological signs of EAE (Huang et al., 2000) , and that initial leukocyte infiltration into the CNS is a prerequisite for intrathecal expression of chemokines (Glabinski et al., 1995) . The initial recruitment of T cells to the CNS is likely to be controlled by CXCL12, which has been shown by others to hold immune cells in the perivascular cuff (McCandless et al., 2006) , and which we show here is present in its intact form only within the perivascular cuff.
We propose that once the right balance of Th1/Th17 cells in the perivascular cuff is reached, and thereby the ratio of TNF-a and IL-17 versus IFN-g is elevated, secretion of mainly activated MMP-9 by astrocytes at the parenchymal border is enhanced. The critical role of proinflammatory cytokines released from infiltrating T cells in this step was demonstrated by transfer of encephalitogenic Tnf À/À T cells to WT recipients, also resulting in enlarged perivascular cuffs and delayed onset of EAE symptoms, reduced CNS chemokine levels, and, most importantly, suppressed gelatinase activity, as observed in mice lacking a resident MMP-2/9 source. Apart from the absence of TNF-a, we show that Tnf À/À T cells have significantly elevated IFN-g levels, but otherwise normal levels of other cytokines, reinforcing that it is not just the absence of TNF-a but rather the balance of different cytokines that modulates MMP secretion and activity at the inflammatory front. We demonstrated a pivotal role for MMP-2 and MMP-9 activity, rather than chemokine levels per se, in promoting T cell migration. Conditioned medium from WT astrocytes constitutively expressed pro-MMP-2 and activated MMP-2 and low levels of pro-MMP-9, which correlated with a basal chemotactic potential that was absent in DKO astrocyte-conditioned medium or when MMP activation was chemically inhibited. This constitutive expression of MMP-2 in the brain (Rosenberg, 2002) probably accounts for leukocyte recruitment during immune surveillance and at EAE induction. However, under inflammatory conditions we showed that TNF-a strongly upregulates not only chemokine expression by astrocytes (Ambrosini et al., 2005) , but also astrocyte MMP-9, and to lesser extent MMP-2, expression and activation, which might enhance chemotactic potential, but only when the astrocytes are capable of secreting active MMP-2 or MMP-9. This is consistent with published data that upregulation of chemokines by intracerebral injection of TNF-a is not sufficient to cause accumulation of leukocytes in the CNS (Glabinski et al., 2003) .
By contrast, the effects of IL-17 and IFN-g on chemokine secretion varied and did not correlate with their enhancing and suppressive effects, respectively, on T cell chemotaxis. Rather, gel zymography, ELISA, and qPCR suggested that IFN-g also can suppress secretion and activation of MMP-9, as reported previously (Di Girolamo et al., 2006) , while IL-17 synergizes with TNF-a to induce both chemokine secretion and MMP expression/activation, and importantly compensates for TNF-a in its absence, as observed in the Tnf À/À mice. These data are consistent with the previously reported moderate effects of IFN-g on chemokine secretion by astrocytes and with EAE data from Ifng -/-mice, which have exacerbated disease symptoms but reduced expression of several key EAE chemokines, including CXCL10, CCL5, and CCL2 (Carter et al., 2007; Tran et al., 2000) , and only moderate upregulation of CCL3 and CCL1 (Tran et al., 2000) . The fact that ablation of astrocyte-derived MMP-2 and MMP-9 activity, either chemically (MOBSAM) or via the use of DKO astrocytes, also significantly reduced the chemotactic capacity of astrocytes, and that this could not be reversed by cytokine treatment but only by MMP-2 or MMP-9 substitution, suggests a key role for the MMPs in chemotaxis. Apart from astrocytes, other sources of MMPs, such as microglial or perivascular cells (McCandless et al., 2006; Meiron et al., 2008) , cannot be excluded and may contribute in vivo. In addition, immune cells also can contribute to MMP-2 and MMP-9 at the parenchymal border, as suggested by the EAE experiments performed with DKO mice carrying WT BM. MMP-2 and MMP-9 can promote early leukocyte migration across the parenchymal border in several ways, including selective cleavage to modulate chemokine activity and/or availability (Van den Steen et al., 2000 Steen et al., , 2003 or promotion of chemokine secretion or release by astrocytes. Our data suggest that both occur in EAE. It is impossible in our model to define precisely which chemokines are affected in which way by the MMPs, due to the limitations of even the most sophisticated mass spectrometry technologies for quantitative analysis of chemokines and their fragments in the small inflammatory foci, and due to the limited availibility of reagents for in vivo chemokine detection. However, this is not the critical point, but rather that MMP-2 or MMP-9 is essential at the inflammatory front and can modulate EAE-relevant chemokines by cleavage and/or induction of their expression, which impacts on whether or not leukocytes can breach the inflammatory front. We demonstrated that one way in which MMP-2 and MMP-9 may induce chemokine expression by astrocytes is via activation of the AKT/NF-kB-signaling pathway (Quinones et al., 2008; Thompson and Van Eldik, 2009 ) in a Notch-1-dependent manner. Notch-1 is expressed by astrocytes (Cau and Blader, 2009) and is cleaved by MMP-9 (Garg et al., 2010) , and possibly also MMP-2, thereby resulting in the inhibition of PTEN and activation of the Akt/NF-kB axis (Garg et al., 2010; van Loo et al., 2006) . However, other pathways are not excluded and require investigation.
A role for MMP-2 and MMP-9 in modulating the activity or availability of chemokines acting on infiltrating leukocytes is supported by the observation that CXCL12 levels were significantly elevated in mice lacking either an immune-cell or tissue-resident source of MMP-2 and MMP-9, while the corresponding levels of the cleaved/inactive form were reduced. Further, although TNF-a is a potent inducer of chemokine secretion by WT astrocytes, TNF-a stimulation of DKO astrocytes could not promote T cell transmigration, and the pro-migration effects of TNF-a/ IL-17 and the suppressive effects of IFN-g were ablated by the inhibition of MMP-2 and MMP-9 and did not strictly correlate with chemokine levels. We showed here that CXCL12 is present in perivascular cuffs of postcapillary venules in the active/uncleaved form, thereby retaining leukocytes in the cuff (McCandless et al., 2006) and probably accounting for the enlarged cuffs observed in the MMP chimeric mice. However, CXCL12 that is expressed or diffuses toward the cuff border and into the CNS parenchyma is inactivated due to the presence of activated MMP-2/9, permitting leukocytes to respond to other chemokines, such as CXCL10, which we showed are localized outside of the cuff and strongly upregulated by MMP-2/9, but not otherwise modulated by MMP-2/9.
Other chemokines such as CCL3 and CCL2 that are abundant in the inflamed CNS are also cleaved by MMP-2/9, resulting in fragments that bind antagonistically to their receptors (McQuibban et al., 2000 (McQuibban et al., , 2002 . Given the broad spectrum of chemokines that are expressed simultaneously in the CNS during EAE, and the varied effects of MMP-2/9 on the different chemokines, it is likely that the sum of these effects determines whether or not the disease-inducing T cells can breach the inflammatory front to induce EAE symptoms. This highlights the strength of a functional readout, as used here, to evaluate chemotactic potential.
In conclusion, during inflammation TNF-a and IL-1 versus IFN-g and IL-17 balance leukocyte migration through induction and/or inhibition of chemokines. We demonstrated that their chemotactic effects are mediated, at least in part, by MMP-9 and MMP-2, and localized these effects to the inflammatory front. Our data illustrate that the cytokine-MMP-chemokine axis defines a network that governs whether or not leukocytes can breach the inflammatory front to transmigrate the parenchymal border and induce disease symptoms. Rather than a single cytokine, the ratio of stimulatory and regulatory cytokines orchestrates leukocyte movement across the parenchymal barrier, features that are relevant to other inflammatory conditions. Although previous studies have implicated MMP-2/9 in EAE and human MS, our data demonstrate that it is not MMP activity per se but rather its in vivo localization that is crucial. The activation of MMP-2/9 precisely at the parenchymal border by cytokines, and, thereby, activation of chemotactic signals at this border, means that, once the leukocytes have transmigrated across the parenchymal border and entered into the CNS parenchyma, the cytokine levels decrease and the chemotactic signal is switched off. This provides initially a self-perpetuating system that then becomes self-limiting, simply by the migration of the leukocytes across the parenchymal border into the CNS parenchyma, a mechanism that would not require high MMP levels but rather depends on the strategic localization of actived MMPs.
EXPERIMENTAL PROCEDURES Animals
Mice employed were C57BL/6, Tnf -/-(Kö rner et al., 1997), Mmp2 -/- (Itoh et al., 1997) , Mmp9 -/- (Dubois et al., 1999) , Notch-1-loxP (Radtke et al., 1999) , and dystroglycan-loxP mice (Moore et al., 2002 (ab25128, Abcam) , and dystroglycan (Vimsa) (Agrawal et al., 2006) .
Immunohistochemistry
Immunofluorescence stainings were performed as described previously (Agrawal et al., 2006) . To measure cuff sizes, brains and spinal cords were oriented in the same position and sectioned entirely from dorsal to ventral. Bound antibodies were visualized using Alexa 488-or Cy3-conjugated goat anti-rat, Cy3-or Cy5-conjugated anti-rabbit secondary antibodies (Jackson ImmunoResearch Laboratories and Molecular Probes), and FITC-anti-CD45 (104, eBioscience). Sections were examined using a Zeiss AxioImager equipped with epifluorescent optics or a Zeiss LSM 700 confocal microscope, and documented using a Hamamatsu ORCA ER camera. Stainings for CXCL10 required fixation of whole brains in 4% paraformaldehyde (PFA) for 90 min at 4 C, embedding in 4% agarose, and sectioning into 200-mm sections. Sections were blocked in 4% normal goat serum plus 3% BSA in 0.5% Triton X-100. Primary and secondary antibody incubations were performed overnight at 4 C. Stainings for CCL3 and the cleaved form of CXCL12 functioned only on 5-10-mm cryosections.
MMPs and Inhibitors
Recombinant MMPs were from R&D Systems. p-Aminophenylmercuric acetate (APMA; Sigma-Aldrich) was used to activate MMP-1, MMP-7, and MMP-8. MMP-3 was employed to activate MMP-2 and MMP-9. MOBSAM, an N-sulphonylamino acid derivative, provided by Shionogi and Company, is a dose-dependent inhibitor of MMPs (Matsumura et al., 2005) . qPCR for MMP-2 and MMP-9 mRNAs was performed using primers listed in the Supplemental Experimental Procedures.
Active and Passive EAE EAE was induced using 35-55 peptide of myelin oligodendrocyte glycoprotein ). Passive transfer of encephalitogenic T cells was as described previously (Wu et al., 2009 ) and anti-IL-4 (10 mg ml MRI MRI measurements to determine brain volumes were performed before and after EAE on a 3T Philips Achieva System (Philips Healthcare) equipped with a 4-cm solenoidal radio frequency coil with heater to maintain body temperature. Mice were anaesthetized by continuous inhalation of 1.5% isofluorane. No gating or triggering during the measurements was used. A 3D gradient echo dataset was acquired in 9:50-min scan time using the following parameters: isotropic resolution, 200 mm, reconstructed to 90 3 90 3 200 mm ; averages, 10. The brain was segmented semimanually using the lasso-tool in the software package amira (Visage Imaging), and the volume was calculated.
Stereology
Following MRI, brains and spinal cords were excised, weighed, and sectioned entirely (ventral to dorsal; approximately 1,000 sections of 5-6 mm/brain); 1 in every 50 sections were stained for CD45 and pan-laminin, and cuff numbers and areas were measured using Volocity 5.5 (Improvision). At least four individual mice per group (i.e., WT, Tnf -/-, DKO mice transferred with WT T cells) were analyzed.
In Situ Hybridization
Frozen sections of EAE brains were fixed in 4% PFA and in situ hybridization was performed as described previously (Frieser et al., 1997) , with the exception that riboprobes were labeled with digoxigenin (DIG)-UTP and detected by sheep anti-digoxygenin alkaline phosphatase, followed by alkaline phosphatase reaction using nitrotetrazolium blue chloride and 5-bromo-4-chloro-3-indolyl. After in situ hybridization, sections were stained with GFAP-Cy3 (Sigma-Aldrich) and DAPI, and imaged using a Zeiss AxioImager. The 385-bp mouse MMP-9 cDNA was generated by PCR using the following primers: 5 0 CATTCGCGTGGATAAGGA3 0 and 5 0 ACAAGAAAGGACGGTGGG 3 0 .
Cytometric Bead Array CD4 + T cells (2 3 10 5 ) were cultured in RPMI medium with MOG 35-55 for 2 days as described above, and cytokine levels in conditioned media were measured using Cytomix kit (Bender MedSystems). All chemokines, except CCL20 and CXCL12, in tissue extracts and conditioned media were measured using Chemomix kit (Bender MedSystems).
ELISA Full-length CXCL12 was measured using the mouse CXCL12/SDF-1 alpha Quantikine ELISA kit (R&D); for cleaved CXCL12, the primary antibody was replaced by anti-CXCL12 5-67 (Vergote et al., 2006) and data were expressed as OD 450 values. CCL20 levels were measured using mouse CCL20 Quantikine ELISA kit (R&D). MMP-2 and MMP-9 activities were measured using the QuickZyme kit (QuickZyme Biosciences).
Flow Cytometry
Mice were perfused with PBS before spleens, LNs, and brains were harvested. Spleens and brains were treated with 2 mg ml -1 collagenase D (Roche Diagnostics) and 1 mg ml -1 DNase I (Roche Diagnostics), and cells were isolated by cell straining (70 mm spleens/100 mm brains). Brain homogenates were separated into neuronal and leukocyte populations by discontinuous density gradient centrifugation using isotonic Percoll (Amersham). The intracellular staining kit (eBioscience) was employed to permeabilize and fix cells, and flow cytometry was performed using a FACS Calibur (Becton Dickinson). Delta-like protein/Fc chimera (R&D) and TRITC-labeled goat anti-mouse IgG Fc (Jackson ImmunoResearch) were employed in flow cytometry for detection of astrocyte expression of Notch-1.
Gelatin Zymography
Gelatin gel and in situ zymography coupled with immunofluorescence staining were performed as described previously (Agrawal et al., 2006) , with the exception that centrifugation concentrated (Amicon) and gelatin-Sepharose prepurified astrocyte condition media were employed in gel zymography. Conditioned media from confluent 48-hr cultures were pooled, concentrated, and purified before use in gel zymography.
Astrocyte Culture
Primary astrocyte cultures were prepared from brains of newborn WT, Mmp2
Mmp9
-/-, and DKO mice as described previously (Agrawal et al., 2006) . Serum-free F12 medium from astrocyte cultures was collected at 24-48 hr for use in in vitro transmigration assays, gel zymography, and chemokine secretion measurements. In some cases, astrocytes were cultured overnight in serum-free F12 plus TNF-a (50 ng ml ) and/or MMP-9 (20 ng ml -1 ); or 10, 50, or 150 nM MOBSAM. Astrocytes were isolated from newborn Notch-1-loxP and dystroglycanloxP mice. Cells were treated with 2 mM recombinant cre-recombinase protein (HTNC) for 20 hr, washed, and cultured in F12 medium for 1 week before testing by flow cytometry using anti-b-dystroglycan antibody or Delta-like protein/Fc chimera plus TRITC-labeled goat anti-mouse IgG Fc.
Transmigration Assays
Transmigration studies were performed with T cells isolated from spleens and LNs at day 14 or 17 after EAE induction using anti-CD4-coated MACS beads. Cells (0.7 3 10 6 ) in 100 ml serum-free DMEM were placed in the upper chamber of a transwell filter (Costar, 5 mm), and transmigration was induced by adding 600 ml serum-free F12 astrocyte-conditioned medium to the lower chamber, 0.1-1 mg ml À1 recombinant chemokines (CXCL12, CXCL10, CCL21) (Promokine) alone, or chemokines plus activated MMP-2 or MMP-9. Experiments were conducted at 37 C for 6 hr, after which the number of cells that had transmigrated into the lower chamber were counted and expressed as a percentage of the total cells added.
Notch-1 Signaling qPCR was used to determine mRNA expression of Hes-1 and Hes-5 using the primers listed in the Supplemental Experimental Procedures. For Notch-1-signaling experiments, astrocytes were untreated or treated for 24 hr with 50 ng ml -1 TNF-a and recombinant activated MMP-2 or MMP-9. Cells were lysed and analyzed by western blotting using the following antibodies: PTEN (D4.3, Cell Signaling Technology), p65 (C22B4, Cell Signaling Technology), Phospho-NF-kB p65 (93H1, Cell Signaling Technology), Phospho-IkB-a (14D4, Cell Signaling Technology), Phospho-AKT (Biosource), total Akt (C67E7, Cell Signaling Technology), and b-Tubulin (Epitomics).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism. All values are expressed as means ± SEM. Data were tested for normality (Kolmogorov-Smirnov test in GraphPad Prism 
